Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.39
▼(-69.61% Downside)
Action:ReiteratedDate:04/10/26
The score is held down primarily by weak financial fundamentals (large ongoing losses, stressed balance sheet with prior negative equity) and bearish technicals (price below key moving averages and negative MACD). Offsetting factors are the recent improvement to positive operating/free cash flow and corporate actions that improve liquidity and restructure obligations, though ongoing Nasdaq listing risk tempers the benefit.
Positive Factors
Non-dilutive licensing and upfront capital
The Future Pak U.S. licensing and supply arrangement delivered meaningful non-dilutive upfront capital and milestone upside while shifting marketing responsibility to a partner. This materially eases near-term liquidity needs, lowers Jaguar’s commercial burden, and allows management to allocate cash and resources to crofelemer development and regulatory milestones over the medium term.
Negative Factors
Negative shareholders' equity and high leverage
Negative equity and elevated leverage materially constrain financial flexibility. With equity deficit and sizable debt, Jaguar faces limited options to fund development organically, greater refinancing risk, and higher cost of capital. This structural capital weakness can impair ability to execute multi-stage rare-disease programs without continued external support or asset sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive licensing and upfront capital
The Future Pak U.S. licensing and supply arrangement delivered meaningful non-dilutive upfront capital and milestone upside while shifting marketing responsibility to a partner. This materially eases near-term liquidity needs, lowers Jaguar’s commercial burden, and allows management to allocate cash and resources to crofelemer development and regulatory milestones over the medium term.
Read all positive factors
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.71M
Dividend YieldN/A
Average Volume (3M)501.13K
Price to Earnings (P/E)―
Beta (1Y)2.36
Revenue Growth12.45%
EPS Growth-544.23%
CountryUS
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)8.97
Shares Outstanding12,419,277
10 Day Avg. Volume425,270
30 Day Avg. Volume501,126
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.13
Price to Sales (P/S)0.19
P/FCF Ratio0.38
Enterprise Value/Market Cap9.23
Enterprise Value/Revenue3.77
Enterprise Value/Gross Profit5.61
Enterprise Value/Ebitda-0.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$2.46M
Jaguar Animal Health Business Overview & Revenue Model
Company Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two ...
How the Company Makes Money
Jaguar Animal Health generates revenue primarily from selling its animal health products (notably anti-diarrheal/GI therapies) through veterinary and animal health distribution channels and, where applicable, direct-to-customer or clinic sales. Ke...
Jaguar Animal Health Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The earnings call presented a positive outlook with significant revenue growth and successful clinical trial results for crofelemer, along with strategic regulatory advancements and expansion plans in the animal health market. However, these positive developments were offset by increased operational losses and net loss attributable to shareholders.Positive Updates
Significant Revenue Growth
The second quarter of 2025 saw a combined net revenue of approximately $3 million, representing a 35% increase compared to Q1 2025 and a 10% increase compared to Q2 2024.
Negative Updates
Increased Net Loss
Net loss attributable to common shareholders increased by approximately $900,000 from $9.5 million in Q2 2024 to $10.4 million in Q2 2025.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Revenue Growth
The second quarter of 2025 saw a combined net revenue of approximately $3 million, representing a 35% increase compared to Q1 2025 and a 10% increase compared to Q2 2024.
Read all positive updates
Company Guidance
During the earnings call for the second quarter of 2025, Jaguar Health reported a combined net revenue of approximately $3 million, marking a 35% increase compared to the first quarter of 2025 and a 10% increase compared to the second quarter of 2024. Mytesi prescription volume rose by 6.5% over the previous quarter. However, the company experienced a loss from operations of $8 million, an increase of $800,000 from the same period in 2024, and a net loss attributable to common shareholders of $10.4 million, up by $900,000. The non-GAAP recurring EBITDA showed a net loss reduction from $8.8 million in 2024 to $7.9 million in 2025. The financial guidance emphasized the importance of recent clinical and regulatory catalysts aiming to secure nondilutive funding and forge business development partnerships.Jaguar Animal Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
14
Very Negative
Cash Flow
42
Neutral
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.51M | 11.69M | 9.76M | 11.96M | 4.33M |
| Gross Profit | 7.74M | 9.73M | 7.72M | 9.94M | 2.00M |
| EBITDA | -45.91M | -36.66M | -32.76M | -33.38M | -42.37M |
| Net Income | -53.58M | -38.49M | -41.30M | -47.45M | -52.59M |
Balance Sheet | |||||
| Total Assets | 38.32M | 53.42M | 50.76M | 47.45M | 53.27M |
| Cash, Cash Equivalents and Short-Term Investments | 968.00K | 8.00M | 6.47M | 5.47M | 17.05M |
| Total Debt | 43.61M | 36.53M | 37.09M | 34.84M | 29.36M |
| Total Liabilities | 57.01M | 46.93M | 45.87M | 48.81M | 41.41M |
| Stockholders Equity | -17.29M | 7.29M | 4.96M | -657.00K | 11.61M |
Cash Flow | |||||
| Free Cash Flow | 5.77M | -29.61M | -33.24M | -34.78M | -34.98M |
| Operating Cash Flow | 5.80M | -29.38M | -33.24M | -33.10M | -34.97M |
| Investing Cash Flow | 149.00K | -231.00K | 0.00 | -1.68M | -6.00K |
| Financing Cash Flow | -44.33M | 31.20M | 34.23M | 23.18M | 43.94M |
Jaguar Animal Health Technical Analysis
Negative
1.28
Price Trends
0.56
Negative
0.84
Negative
1.48
Negative
Market Momentum
-0.06
Negative
38.32
Neutral
50.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 1.28 is above the 20-day moving average (MA) of 0.42, above the 50-day MA of 0.56, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 38.32 is Neutral, neither overbought nor oversold. The STOCH value of 50.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.
Jaguar Animal Health Risk Analysis
Jaguar Animal Health disclosed 65 risk factors in its most recent earnings report. Jaguar Animal Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The growing use of AI systems to automate processes, analyze data, and support decision-making poses inherent risks. Q4, 2023
Jaguar Animal Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $11.75M | ― | -248.01% | ― | ― | 53.13% | |
45 Neutral | $4.71M | ― | 9999.00% | ― | 12.45% | -544.23% | |
44 Neutral | $4.87M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $5.18M | -0.31 | -46.34% | ― | ― | 70.71% | |
43 Neutral | $4.59M | -0.18 | -212.63% | ― | 192.72% | 83.61% | |
42 Neutral | $4.58M | -2.23 | -0.40% | ― | ― | 96.26% |
* Healthcare Sector Average
JAGX
Jaguar Animal Health
0.38
-5.19
-93.20%
GLMD
Galmed Pharmaceuticals
0.79
-0.54
-40.53%
SNGX
Soligenix
1.14
-1.04
-47.71%
REVB
Revelation Biosciences
1.23
-36.93
-96.78%
DRMA
Dermata Therapeutics
1.21
-6.87
-85.02%
SXTP
60 Degrees Pharmaceuticals, Inc.
1.74
-10.10
-85.30%
Jaguar Animal Health Corporate Events
Delistings and Listing ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Jaguar Animal Health Regains Nasdaq Compliance Through Capital Infusions
Positive
Apr 9, 2026
Jaguar Health, Inc. reported that as of December 31, 2025, it had a stockholders’ deficit of approximately $18.7 million, which left the company out of compliance with Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5 million in stockho...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Animal Health Restructures Debt and Royalty Agreements
Positive
Mar 9, 2026
On March 6, 2026, Jaguar Health amended two $12 million royalty agreements with Uptown Capital and Streeterville Capital, delaying the start of monthly royalty payments from April 1, 2026 to July 1, 2026 and cutting each Royalty Repayment Amount b...
Delistings and Listing ChangesRegulatory Filings and Compliance
Jaguar Health Faces Nasdaq Delisting, Plans to Appeal
Negative
Mar 6, 2026
On March 5, 2026, Jaguar Health disclosed that it had received notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days and that, due to its prior large reverse stock splits, it is not ...
DividendsRegulatory Filings and Compliance
Jaguar Animal Health Declares Special Series O Dividend
Neutral
Mar 3, 2026
On February 18, 2026, Jaguar Health’s board declared a special one-time dividend of one-tenth of a share of newly designated Series O Convertible Preferred Stock for each share of common stock outstanding, plus certain eligible warrants, wit...
Business Operations and StrategyDividends
Jaguar Health Declares Special Convertible Preferred Stock Dividend
Positive
Feb 18, 2026
On February 18, 2026, Jaguar Health announced that its board had declared a one-time special stock dividend of Series O convertible preferred shares for holders of its common stock and certain warrants of record on March 2, 2026, with payment sche...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Health Executes Debt-Reducing Equity Warrant Transactions
Neutral
Jan 23, 2026
On January 16, 2026, Jaguar Health executed a series of privately negotiated exchanges with Iliad Research and Trading and Streeterville Capital that reduced outstanding royalty interests and retired portions of its Series L and Series M perpetual...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Animal Health Grants U.S. Rights to Crofelemer Drugs
Positive
Jan 15, 2026
On January 12, 2026, Jaguar Health’s subsidiary Napo Pharmaceuticals entered into a U.S. licensing and supply arrangement with Woodward Specialty, an affiliate of Future Pak, under which Future Pak becomes the exclusive U.S. marketer of Jagu...
Private Placements and Financing
Jaguar Animal Health Raises Short-Term Capital Through Notes
Neutral
Jan 12, 2026
On January 6, 2026, Jaguar Health, Inc. entered into securities purchase agreements with two accredited investors and closed a financing in which it issued $350,000 in unsecured promissory notes bearing 6% annual interest and maturing one month af...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.